Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA:600521)

SHA:600521 Revenue

Zhejiang Huahai Pharmaceutical had revenue of 2.51B CNY in the quarter ending September 30, 2026, with 32.75% growth. This brings the company's total for the last twelve months to 9.60B, up 10.27% year-over-year. In the year 2025, Zhejiang Huahai Pharmaceutical had annual revenue of 8.59B, down -10.06%. That makes Zhejiang Huahai Pharmaceutical the 6,130th largest company in the world by revenue and 836th in China.

• Revenue (ttm): 9.60B
• Revenue Growth: +10.27%
• P/S Ratio: 2.52
• Revenue / Employee: 1.09M
• Employees: 8,797
• Market Cap: 24.23B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Sales of Drug Product 5.00B 58.3%
• Sales of Raw Materials and Intermediates 3.47B 40.4%
• Others 69.75M 0.8%
• Technical Services 44.90M 0.5%

By Geography

Chart

• China 4.30B 50.1%
• Foreign 4.28B 49.9%

Fiscal year ended Dec 31, 2025 See the full SHA:600521 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	8.59B	-960.28M	-10.06%
Dec 31, 2024	9.55B	1.24B	14.91%
Dec 31, 2023	8.31B	42.97M	0.52%
Dec 31, 2022	8.27B	1.62B	24.42%
Dec 31, 2021	6.64B	158.36M	2.44%

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error